Clinical Trial Update: Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF) [Phase 1]

View source ↗

Summary

Phase 1 trial of autologous, lethally irradiated melanoma cells engineered by adenoviral gene transfer to secrete GM-CSF; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• sargramostim (sargramostim)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Melanoma | Phase 1 | Status: COMPLETED